Arnaud Scherpereel
Expertise in
6
conditions

Arnaud Scherpereel

CHU Lille
Lille, FR 
Expertise in
6
conditions
CHU Lille
Lille, FR 

Overview

Arnaud Scherpereel practices practicing medicine in Lille, France.

Mr. Scherpereel is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Mesothelioma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 148 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

CHU Lille
Lille, 59037, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
Enrollment Status: Completed
Publish Date: April 21, 2026
Intervention Type: Biological, Drug
Study Drugs: rAd-IFN, Celecoxib, Gemcitabine
Study Phase: Phase 3
Circulating Tumor Cells and Early Diagnosis of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease
Circulating Tumor Cells and Early Diagnosis of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: March 24, 2026
Intervention Type: Biological
Study Phase: Not Applicable
Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation
Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation
Enrollment Status: Terminated
Publish Date: March 17, 2026
Intervention Type: Biological, Procedure, Drug
Study Phase: Not Applicable
Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of Integrating the Addiction Treatment to the Initial Cancer Treatment Program
Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of Integrating the Addiction Treatment to the Initial Cancer Treatment Program
Enrollment Status: Completed
Publish Date: March 13, 2026
Intervention Type: Procedure
Study Phase: Not Applicable
Pilot Study of the Feasibility of Intrapleural Photodynamic Therapy in a Multimodal Treatment Combining Extended Pleurectomy/Decortication, Adjuvant Chemotherapy and Prophylactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
Pilot Study of the Feasibility of Intrapleural Photodynamic Therapy in a Multimodal Treatment Combining Extended Pleurectomy/Decortication, Adjuvant Chemotherapy and Prophylactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
Enrollment Status: Completed
Publish Date: February 05, 2026
Intervention Type: Device, Drug, Procedure
Study Phase: Phase 2
A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy
A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy
Enrollment Status: Completed
Publish Date: February 01, 2024
Intervention Type: Drug
Study Drug: MesoPher
Study Phase: Phase 2/Phase 3
A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function
A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function
Enrollment Status: Completed
Publish Date: April 09, 2021
Intervention Type: Drug
Study Phase: Phase 2
Home Respiratory Rehabilitation in Patients With Lung Cancer Non-small Cell Advanced or Metastatic Treated With Oral Targeted Therapy
Home Respiratory Rehabilitation in Patients With Lung Cancer Non-small Cell Advanced or Metastatic Treated With Oral Targeted Therapy
Enrollment Status: Terminated
Publish Date: May 16, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 7 Less Clinical Trials

148 Total Publications

Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".
Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 10, 2026

Frequently Asked Questions about Arnaud Scherpereel

Is Arnaud Scherpereel a top-rated expert for Mesothelioma?

MediFind is an objective health platform that identifies experts based on real-world data. Arnaud Scherpereel is classified as an Elite expert for Mesothelioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Arnaud Scherpereel participate in research or clinical trials?

Yes. Arnaud Scherpereel has published 148 articles and abstracts on conditions like Mesothelioma. You can view a list of Arnaud Scherpereel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Scherpereel's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile